Novartis and Molecular Partners Initiate P-II/III EMPATHY Study to Evaluate Ensovibep (MP0420) for the Treatment of COVID-19

May 27, 2021 Auto Bot Clinical Trials, Molecular Partners, Novartis 0

Shots:

  • The P-II/II EMPATHY study will evaluate the safety & efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, to prevent worsening symptoms and hospitalization. The P-II study will enroll 400 patients in the P-II part to identify dose, with anticipated results in Aug’2021
  • P-III part will be conducted with additional 1,700 patients, with expected results in H1’21. Novartis will lead the clinical program for ensovibep while Molecular Partners will sponsor the studies
  • If EMPATHY results are positive, Novartis is planning to seek the FDA’s EUA for the DARPin therapeutic candidate

Click here to­ read full press release/ article | Ref: Novartis | Image: Clinical Trials Arena

The post Novartis and Molecular Partners Initiate P-II/III EMPATHY Study to Evaluate Ensovibep (MP0420) for the Treatment of COVID-19 first appeared on PharmaShots.